TEXAS CANCER INTERCEPTION INSTITUTE Trademark
Trademark Overview
On Thursday, July 6, 2023, a trademark application was filed for TEXAS CANCER INTERCEPTION INSTITUTE with the United States Patent and Trademark Office. The USPTO has given the TEXAS CANCER INTERCEPTION INSTITUTE trademark a serial number of 98072826. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, March 22, 2024. This trademark is owned by Baylor Scott & White Holdings. The TEXAS CANCER INTERCEPTION INSTITUTE trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:
Medical testing for diagnostic or treatment purposes in the field of oncology; cancer screening services; medical services; providing medical information; providing healthcare services and healthcare information in the field of cancer and oncology
Scientific testing and research services in the field of oncology; providing medical research services in the field of cancer and oncology; providing clinical scientific testing services and medical research in the field of oncology and cancer prevention and treatment; medical and scientific research, namely, conducting clinical trials for others; providing medical information and data and medical research in the field of oncology; promoting research in the field of oncology
General Information
Serial Number | 98072826 |
Word Mark | TEXAS CANCER INTERCEPTION INSTITUTE |
Filing Date | Thursday, July 6, 2023 |
Status | 641 - NON-FINAL ACTION - MAILED |
Status Date | Friday, March 22, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
Goods and Services | Medical testing for diagnostic or treatment purposes in the field of oncology; cancer screening services; medical services; providing medical information; providing healthcare services and healthcare information in the field of cancer and oncology |
Goods and Services | Scientific testing and research services in the field of oncology; providing medical research services in the field of cancer and oncology; providing clinical scientific testing services and medical research in the field of oncology and cancer prevention and treatment; medical and scientific research, namely, conducting clinical trials for others; providing medical information and data and medical research in the field of oncology; promoting research in the field of oncology |
Classification Information
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Sunday, August 6, 2023 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Sunday, August 6, 2023 |
Primary Code | 044 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
Party Name | Baylor Scott & White Holdings |
Party Type | 10 - Original Applicant |
Legal Entity Type | 99 - Other |
Address | Dallas, TX 75246 |
Trademark Events
Event Date | Event Description |
Monday, July 10, 2023 | NEW APPLICATION ENTERED |
Sunday, August 6, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Monday, March 18, 2024 | ASSIGNED TO EXAMINER |
Monday, June 10, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
Monday, June 10, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
Friday, March 22, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Friday, March 22, 2024 | NON-FINAL ACTION WRITTEN |
Friday, March 22, 2024 | NON-FINAL ACTION E-MAILED |